Novo Nordisk CEO steps down amid market challenges, including competition from Eli Lilly's rival drug and setbacks with Novo Nordisk's obesity treatments.
US considers controversial plan to relocate Palestinians from Gaza to unstable Libya
Novo Nordisk CEO steps down amid market challenges, including competition from Eli Lilly's rival drug and setbacks with Novo Nordisk's obesity treatments.
US considers controversial plan to relocate Palestinians from Gaza to unstable Libya